Adrienne Choma, Co-Founder of Saladax Biomedical, Named One of National Winners of 2013 EY Entrepreneurial Winning Women™ Program Adrienne Choma is One of 12 Winners Recognized Nationwide With This Prestigious Award
BETHLEHEM, Pa., Nov. 15, 2013 /PRNewswire-iReach/ -- Today, Adrienne Choma, Esq., Co-Founder, Sr. VP and COO of Saladax Biomedical, Inc. was named one of 12 winners of the EY 2013 class of Entrepreneurial Winning Women, a national competition and ongoing executive leadership program that identifies high-potential women entrepreneurs whose businesses show real potential to scale. This year's diverse class represents some of the best and brightest women in business today. Together, the 12 Winning Women have an average of $7.8 million in yearly sales, 42 employees, and seven years in business.
Saladax Biomedical, Inc. is a privately held company developing and commercializing the MyCare™ line of novel diagnostic tests that help oncologists tailor cancer drug dosing to individual patient needs for optimized treatment effectiveness and reduced chemotherapy-associated side effects. "I am thrilled to have been selected as a 2013 Entrepreneurial Winning Woman and to be in the company of such an accomplished group of co-winners and alumni of the program. I foresee EY providing very valuable guidance in helping Saladax achieve its goal of changing the paradigm of chemotherapy dosing for better cancer patient care," said Ms. Choma.
The Entrepreneurial Winning Women program is conducted in collaboration with several organizations that encourage the development of women-owned businesses, including the Women Presidents' Organization (WPO), the Women's Business Enterprise National Council (WBENC), the National Association of Women Business Owners (NAWBO), The Committee of 200 (C200), the Kauffman Foundation and Babson College's Center for Women's Leadership. For more information on the program, visit www.ey.com/us/entrepreneurialwinningwomen.
Saladax Biomedical is a leader in the development and deployment of high quality diagnostic services and products, delivering actionable data to help physicians select and optimize the use of current and new pharmaceutical products, with the goals of improving health and positively impacting the economics of care. Saladax also serves as a valuable collaborator for pharmaceutical and biotechnology companies in the development of companion diagnostics, addressing multiple risks and challenges encountered in drug development.
Headquartered in Bethlehem, Pennsylvania, Saladax was founded in 2004 and is ISO 13485:2003 certified. Saladax Biomedical Laboratories is certified and registered under the Clinical Laboratory Improvement Act (CLIA) regulations by the Office of Clinical Standards and Quality (OCSQ), a division of The Centers for Medicare & Medicaid Services (CMS) that regulates laboratory testing performed on humans.
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.
EY refers to the global organization and may refer to one or more of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.
Media Contact: Lorraine Damico, MBA, Saladax Biomedical Inc., 484-547-0529, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Saladax Biomedical